Clinical improvement (reduced inflammation, stable organ function) is reported in approximately 65–70% of treated cohorts in early trials. However, 'success' varies by metric—some patients show antibody titre reduction, others primarily symptomatic relief. Remission induction (complete drug-free resolution) remains rare; most benefit takes the form of reduced relapse frequency or lower maintenance steroid doses over 12–24 months.
Registered trial data spans phase I safety through phase II efficacy work across global centres. Representative studies report disease activity index improvements in 60–75% of infused cohorts over 12 months, with renal histology stabilisation in 40–55% of lupus nephritis cases. Cytokine profiling shows durable reduction in pro-inflammatory markers (TNF-α, IL-6) persisting 6–9 months post-infusion. No completed phase III pivotal trial has yet reported, making this investigational rather than standard-of-care.
Съм ли кандидат? → · Lupus (SLE): full overview → · Цена Лупус (SLE) → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка